SlowBull
The Business Brief SATURDAY, 8 AUGUST 2026
← All stories
Markets

STAT+: Biotech’s next big bet: A Tenax study of a heart failure treatment

1 source ·1 article ·Aug 6, 10:30 UTC

Tenax Therapeutics will soon report results from a Phase 3 study that is one of the biggest binary biotech stock events remaining in the sector this year.

Covered by 1 outlet

Statnews 1

All coverage · 1 article

STAT News ·Aug 6, 10:30 UTC

STAT+: Biotech’s next big bet: A Tenax study of a heart failure treatment

Tenax Therapeutics will soon report results from a Phase 3 study that is one of the biggest binary biotech stock events remaining in the sector this year.